Shanghai pharma company wins put-option dispute
A Shanghai-based pharmaceutical company has sought to enforce an ICDR award worth over US$40 million against the founder of a New Jersey-based medical practices network who has been implicated in a bank fraud conspiracy.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.